China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category 1 drug candidate BPI-460372 has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication for the drug is advanced solid tumors, marking a significant step forward in the development of innovative cancer therapies.
BPI-460372: Targeting the Hippo Signaling Pathway
BPI-460372 is an in-house developed new molecular entity (NME) that targets the Hippo signaling pathway. Specifically, it is a small molecule inhibitor of the transcriptional enhanced associate domain (TEAD). Preclinical studies have demonstrated that BPI-460372 exhibits excellent in vitro and in vivo activities, along with favorable pharmacokinetic properties and good safety. Currently, there is no similar product on the market anywhere in the world.
Future Outlook
The acceptance of the clinical trial filing for BPI-460372 by the NMPA underscores Betta Pharmaceuticals’ commitment to advancing innovative treatments for advanced solid tumors. This development highlights the company’s focus on addressing unmet medical needs in oncology and positions it at the forefront of research into the Hippo signaling pathway.-Fineline Info & Tech
